



Osivax Expands Executive Team to Strengthen Corporate Expansion and Accelerate the Development of Universal Flu Vaccine Candidate

-- Linda Lebon joins as Chief Regulatory Officer --

-- Florian Sourd joins as VP Finance --

Lyon, France – October 30, 2019 – Osivax announced today the appointment of Linda Lebon as Chief Regulatory Officer and Florian Sourd as VP Finance. Linda brings more than 25 years' experience in regulatory affairs and will play a critical role in defining the regulatory pathway for development and clinical programmes and will support the Company as it advances these programmes toward commercialisation. Florian has 10 years of experience in corporate finance and financial services and will support the Company international corporate development.

"As our flagship project, OVX836 universal flu vaccine candidate is about to enter phase 2a clinical trial, we are delighted to welcome these two personalities whose solid experience and established skillsets will be crucial in supporting our international development," commented Alexandre Le Vert, CEO and co-founder of Osivax. "Linda and Florian will provide major contributions to developing and executing our Corporate strategy and help accelerate our ambitious clinical development plan"

Linda Lebon, Chief Regulatory Officer

Linda Lebon is a strategic regulatory expert with more than 25 years of experience in regulatory affairs. During her career, she has provided regulatory support to companies in strategic global drug development for both clinical and non-clinical projects. Until recently, she was Vice President Regulatory Affairs at Argenx, a clinical-stage biotechnology company focused on developing antibodies for autoimmune disease and cancer.

Linda has held positions in several large pharmaceutical companies as well as senior positions in regulatory CROs and advisory firms, including Quintiles and Voisin Life Sciences. As an independent consultant, she has also supported several notable fast-growing life sciences companies including Celyad, Mithra and iTeos Therapeutics, in their product developments in Europe, America and Japan. In these roles she has been closely involved with the transitional process between R&D activities and the regulatory stage of development.

Florian Sourd, VP Finance

Florian has 10-years' experience in corporate finance. He has a mix of experience in corporate finance and financial services. After several entrepreneurship experiences in parallel of his scholarship at EM Lyon in France, he worked as financial controller for a media group and acted as financial director for an SME as it was being acquired by a larger group.



His experience in financial services ranges from M&A advice at BNP Paribas, to financial audit at Ernst & Young, as well as transaction services at Deloitte for French and International mid to large size companies. Over the last two years, Florian was involved more specifically in healthcare transactions for diagnostic companies and healthcare provider groups.

Florian will play a critical role in supporting the company international expansion.

About Osivax

Osivax's mission is to revolutionize influenza prevention with a universal flu vaccine for both current and future Influenza infections by leveraging its unique oligoDOM[®] technology platform. OVX836 universal flu vaccine candidate is in Phase 1 clinical development. Osivax is focused on providing proof-of-concept in Influenza firstly to save lives and secondly to apply the oligoDOM[®] platform to other infectious and immune system-associated diseases. For further information: www.osivax.com

Osivax

Alexandre Le Vert, CEO

contact@osivax.com

+33 (0)4 37 65 55 03

For Media Inquiries:

Trophic Communications

Joanne Tudorica or Valeria Fisher

tudorica@trophic.eu or fisher@trophic.eu

+49 176 2103 7191